CMPX vs. TSHA

Last updated Apr 1, 2026

Compare and contrast key facts about Compass Therapeutics Inc. (CMPX) and Taysha Gene Therapies, Inc. (TSHA).

Performance

CMPX vs. TSHA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Compass Therapeutics Inc. (CMPX) and Taysha Gene Therapies, Inc. (TSHA). The values are adjusted to include any dividend payments, if applicable.

CMPX vs. TSHA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
CMPX Compass Therapeutics Inc.	-1.49%	270.34%	-7.05%	-68.99%	58.68%	-62.71%
TSHA Taysha Gene Therapies, Inc.	-18.73%	217.92%	-2.26%	-21.68%	-80.60%	-41.72%

Fundamentals

Market Cap CMPX : $977.82M TSHA : $1.43B
EPS CMPX : -$0.43 TSHA : -$0.34
PB Ratio CMPX : 4.97 TSHA : 5.79
Total Revenue (TTM) CMPX : $0.00 TSHA : $9.77M
Gross Profit (TTM) CMPX : $0.00 TSHA : $6.30M
EBITDA (TTM) CMPX : -$52.54M TSHA : -$108.26M

Returns By Period

In the year-to-date period, CMPX achieves a -1.49% return, which is significantly higher than TSHA's -18.73% return.

CMPX

• 1D: 3.73%
• 1M: -6.37%
• YTD: -1.49%
• 6M: 51.14%
• 1Y: 178.42%
• 3Y*: 17.39%
• 5Y*: —
• 10Y*: —

TSHA

• 1D: 9.83%
• 1M: -1.32%
• YTD: -18.73%
• 6M: 36.70%
• 1Y: 221.58%
• 3Y*: 77.63%
• 5Y*: -26.04%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CMPX vs. TSHA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CMPX

CMPX Risk / Return Rank: 91
CMPX Sharpe Ratio Rank: 94
CMPX Sortino Ratio Rank: 89
CMPX Omega Ratio Rank: 88
CMPX Calmar Ratio Rank: 93
CMPX Martin Ratio Rank: 93

TSHA

TSHA Risk / Return Rank: 91
TSHA Sharpe Ratio Rank: 93
TSHA Sortino Ratio Rank: 94
TSHA Omega Ratio Rank: 90
TSHA Calmar Ratio Rank: 91
TSHA Martin Ratio Rank: 87

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CMPX vs. TSHA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Compass Therapeutics Inc. (CMPX) and Taysha Gene Therapies, Inc. (TSHA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CMPX	TSHA	Difference
Sharpe ratio Return per unit of total volatility	2.46	2.35	+0.11
Sortino ratio Return per unit of downside risk	2.83	3.33	-0.51
Omega ratio Gain probability vs. loss probability	1.37	1.40	-0.03
Calmar ratio Return relative to maximum drawdown	4.76	4.23	+0.54
Martin ratio Return relative to average drawdown	13.90	9.01	+4.89
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CMPX vs. TSHA - Sharpe Ratio Comparison

The current CMPX Sharpe Ratio is 2.46, which is comparable to the TSHA Sharpe Ratio of 2.35. The chart below compares the historical Sharpe Ratios of CMPX and TSHA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CMPX	TSHA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.46	2.35	+0.11
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.19	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.11	-0.20	+0.09

Correlation

The correlation between CMPX and TSHA is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CMPX vs. TSHA - Dividend Comparison

Neither CMPX nor TSHA has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CMPX vs. TSHA - Drawdown Comparison

The maximum CMPX drawdown since its inception was -90.91%, smaller than the maximum TSHA drawdown of -98.14%. Use the drawdown chart below to compare losses from any high point for CMPX and TSHA.

Drawdown Indicators

	CMPX	TSHA	Difference
Max Drawdown Largest peak-to-trough decline	-90.91%	-98.14%	+7.23%
Max Drawdown (1Y) Largest decline over 1 year	-34.82%	-31.13%	-3.69%
Max Drawdown (5Y) Largest decline over 5 years	—	-97.76%	—
Current Drawdown Current decline from peak	-39.89%	-85.92%	+46.03%
Average Drawdown Average peak-to-trough decline	-65.86%	-76.71%	+10.85%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.93%	14.60%	-2.67%

Volatility

CMPX vs. TSHA - Volatility Comparison

The current volatility for Compass Therapeutics Inc. (CMPX) is 14.82%, while Taysha Gene Therapies, Inc. (TSHA) has a volatility of 21.10%. This indicates that CMPX experiences smaller price fluctuations and is considered to be less risky than TSHA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CMPX	TSHA	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.82%	21.10%	-6.28%
Volatility (6M) Calculated over the trailing 6-month period	42.80%	65.51%	-22.71%
Volatility (1Y) Calculated over the trailing 1-year period	73.21%	99.28%	-26.07%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	83.91%	136.33%	-52.42%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	83.91%	131.85%	-47.94%

Financials